219 related articles for article (PubMed ID: 32870522)
1. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Jiang Q; Ghafoor A; Mian I; Rathkey D; Thomas A; Alewine C; Sengupta M; Ahlman MA; Zhang J; Morrow B; Steinberg SM; Pastan I; Hassan R
Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32611684
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
[TBL] [Abstract][Full Text] [Related]
7. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
Scales SJ; Gupta N; Pacheco G; Firestein R; French DM; Koeppen H; Rangell L; Barry-Hamilton V; Luis E; Chuh J; Zhang Y; Ingle GS; Fourie-O'Donohue A; Kozak KR; Ross S; Dennis MS; Spencer SD
Mol Cancer Ther; 2014 Nov; 13(11):2630-40. PubMed ID: 25249555
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.
Alewine C; Ahmad M; Peer CJ; Hu ZI; Lee MJ; Yuno A; Kindrick JD; Thomas A; Steinberg SM; Trepel JB; Figg WD; Hassan R; Pastan I
Clin Cancer Res; 2020 Feb; 26(4):828-836. PubMed ID: 31792036
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Kreitman RJ; Hassan R; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2009 Aug; 15(16):5274-9. PubMed ID: 19671873
[TBL] [Abstract][Full Text] [Related]
10. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.
Liu W; Tai CH; Liu X; Pastan I
Proc Natl Acad Sci U S A; 2022 Nov; 119(48):e2214928119. PubMed ID: 36409889
[TBL] [Abstract][Full Text] [Related]
11. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Weldon JE; Xiang L; Zhang J; Beers R; Walker DA; Onda M; Hassan R; Pastan I
Mol Cancer Ther; 2013 Jan; 12(1):48-57. PubMed ID: 23136186
[TBL] [Abstract][Full Text] [Related]
12. The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.
Liu XF; FitzGerald DJ; Pastan I
Cancer Res; 2013 Apr; 73(7):2281-8. PubMed ID: 23348423
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
Ali-Rahmani F; FitzGerald DJ; Martin S; Patel P; Prunotto M; Ormanoglu P; Thomas C; Pastan I
Cancer Res; 2016 Mar; 76(6):1560-8. PubMed ID: 26719540
[TBL] [Abstract][Full Text] [Related]
16. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
Zhang YF; Phung Y; Gao W; Kawa S; Hassan R; Pastan I; Ho M
Sci Rep; 2015 May; 5():9928. PubMed ID: 25996440
[TBL] [Abstract][Full Text] [Related]
17. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
18. Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.
El-Behaedi S; Landsman R; Rudloff M; Kolyvas E; Albalawy R; Zhang X; Bera T; Collins K; Kozlov S; Alewine C
Toxins (Basel); 2018 Oct; 10(11):. PubMed ID: 30384408
[TBL] [Abstract][Full Text] [Related]
19. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel.
Pegna GJ; Lee MJ; Peer CJ; Ahmad MI; Venzon DJ; Yu Y; Yuno A; Steinberg SM; Cao L; Figg WD; Donahue RN; Hassan R; Pastan I; Trepel JB; Alewine C
Cancer Med; 2023 Feb; 12(4):4236-4249. PubMed ID: 36208017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
